文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

MiR-155通过抑制TGF-β激活结合蛋白2诱导自噬减轻脓毒症肺损伤

MiR-155 Alleviates Septic Lung Injury by Inducing Autophagy Via Inhibition of Transforming Growth Factor-β-Activated Binding Protein 2.
PubMed 文献 · Shock · 2017-01-01
一句话结论小鼠及细胞模型显示miR-155通过抑制TAB2诱导自噬减轻脓毒症肺损伤炎症,脓毒症肺损伤患者BALF中miR-155表达升高。

该研究纳入接受纤维支气管镜检查的脓毒症肺损伤患者采集支气管肺泡灌洗液(BALF),并以盲肠结扎穿孔法建立小鼠脓毒症肺损伤模型、脂多糖(LPS)处理NR8383肺泡巨噬细胞系。结果显示脓毒症肺损伤患者BALF、小鼠模型及LPS处理的NR8383细胞中miR-155表达均升高,小鼠和巨噬细胞模型中自噬体数量增多。经气道转染agomir miR-155的小鼠炎症减轻、肺组织含水量降低、自噬体数量增多、LC3 II/I表达升高、Caspase-1和TAB2表达降低、细胞因子水平下降;LPS处理的巨噬细胞获得类似结果;转染miR-155抑制剂的细胞TAB2和Caspase-1表达升高、自噬体减少、LC3 II/I表达降低、细胞因子水平升高。作者结论认为miR-155通过抑制TAB2诱导自噬减轻脓毒症肺损伤炎症。

要点

  • 脓毒症肺损伤患者BALF中miR-155表达升高,小鼠脓毒症肺损伤模型及LPS处理的NR8383巨噬细胞中miR-155表达亦升高。
  • 经气道转染agomir miR-155的小鼠肺组织含水量降低、炎症减轻、自噬体数量增多、LC3 II/I表达升高。
  • miR-155转染小鼠Caspase-1和TAB2表达降低、细胞因子水平下降;LPS处理的巨噬细胞转染miR-155 mimic后获得类似结果。
  • 转染miR-155抑制剂的细胞TAB2和Caspase-1表达升高、自噬体减少、LC3 II/I表达降低、细胞因子水平升高。
  • 作者认为miR-155通过抑制TAB2诱导自噬减轻脓毒症肺损伤炎症,证据来自小鼠模型和细胞实验。

适用人群与场景

  • 接受纤维支气管镜检查的脓毒症肺损伤患者(用于采集BALF样本)
  • 盲肠结扎穿孔法建立脓毒症肺损伤模型的小鼠
  • LPS处理的NR8383肺泡巨噬细胞系

处置流程与药物剂量

  • 小鼠经气道转染agomir miR-155以诱导miR-155表达
  • NR8383巨噬细胞转染miR-155 mimic、miR-155 inhibitor或TAB2-siRNA

研究设计与关键结果

  • 研究类型为小鼠模型和体外细胞实验,并纳入接受纤维支气管镜检查的脓毒症肺损伤患者采集BALF。
  • 脓毒症肺损伤患者BALF、小鼠模型及LPS处理的NR8383巨噬细胞中miR-155表达升高。
  • 小鼠和巨噬细胞模型中自噬体数量增多。
  • 经气道转染agomir miR-155的小鼠炎症减轻、肺组织含水量降低、自噬体数量增多、LC3 II/I表达升高、Caspase-1和TAB2表达降低、细胞因子水平下降。
  • LPS处理的巨噬细胞转染miR-155 mimic后获得与小鼠类似的結果。
  • 转染miR-155抑制剂的细胞TAB2和Caspase-1表达升高、自噬体减少、LC3 II/I表达降低、细胞因子水平升高。

证据类型、等级与局限

  • 证据类型:小鼠模型和体外细胞实验,并纳入患者BALF样本。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 作者认为miR-155通过抑制TAB2诱导自噬减轻脓毒症肺损伤炎症,该结论来自小鼠模型和细胞实验。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The anti-inflammatory effect of miR-155 was closely linked to transforming growth factor-β-activated kinase-1-binding protein 2 (TAB2) and autophagy. This study investigated the role of miR-155 in attenuation of septic lung injury through TAB2 and autophagy in mouse model and in vitro.

METHODS: Patients who underwent fiberoptic bronchoscope examination with or without septic lung injury were recruited for the collection of bronchoalveolar lavage fluid (BALF) samples. Mouse model of septic lung injury was established by cecal ligation puncture, while alveolar macrophage cell line was treated with lipopolysaccharide (LPS). Agomir miR-155 transfection into the mouse airways was performed to induce miR-155 expression, while miR-155 mimic, miR-155 inhibitor, or TAB2-siRNA was transfected into NR8383 macrophages. Mouse BALF and cell cytokine levels, lung tissue pathology and wet/dry ratio, numbers of autophagy bodies, miR-155, gene and protein expressions were also examined accordingly.

RESULTS: Expression of miR-155 was increased in the BALF of septic lung injury patients, in mouse model and NR8383 macrophages after LPS treatment. Increased numbers of autophagy bodies were also observed in mouse and macrophage models. MiR-155-transfected mice showed alleviation of inflammation, lower water content in lung tissues, increased number of autophagy bodies, increased expression of microtubule-associated protein 1 light chain 3 (LC3 II/I), reduced expressions of cysteinyl aspartate-specific protease-1 (Caspase-1), and TAB2, and decreased cytokines levels. Similar results were obtained in macrophages after LPS treatment. Cells transfected with miR-155 inhibitor showed increased expression of TAB2 and Caspase-1, fewer autophagy bodies, lower LC3 II/I expression, and higher cytokine levels.

CONCLUSION: The current study observed a higher level of miR-155 in the BALF from sepsis patients with acute respiratory distress syndrome and demonstrated that miR-155 alleviated inflammation in septic lung injury in mouse and cell models by inducing autophagy via inhibition of TAB2.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Liu F, Nie C, Zhao N, et al. MiR-155 Alleviates Septic Lung Injury by Inducing Autophagy Via Inhibition of Transforming Growth Factor-β-Activated Binding Protein 2. Shock. 2017. PMID: 28125526. doi:10.1097/SHK.0000000000000839

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。